Genovis AB (FRA:5GV) ROE % Adjusted to Book Value: 1.64% (As of Mar. 2026)

Genovis AB FRA:5GV +4.19% 93 ROE % Adjusted to Book Value is 1.64% as of Mar. 2026. GuruFocus rates FRA:5GV with a GF Score™ of 93/100 and a GF Value™ of €2.57. The stock has 3 warning signs investors should review.

Genovis AB's ROE % for the quarter that ended in Mar. 2026 was 6.23%. Genovis AB's PB Ratio for the quarter that ended in Mar. 2026 was 3.80. Genovis AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 1.64%.

Genovis AB ROE % Adjusted to Book Value Related Terms

Genovis AB ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Genovis AB's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovis AB ROE % Adjusted to Book Value Chart

Genovis AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

0.58

0.39

2.10

2.27

1.92

Genovis AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															1.20	1.23	2.28	2.06	1.64

FRA:5GV vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Genovis AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genovis AB ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovis AB's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Genovis AB's ROE % Adjusted to Book Value falls into.

Save Embed

93GF Score

Genovis AB FRA:5GV

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Genovis AB ROE % Adjusted to Book Value Calculation

Genovis AB's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	9.64%	/	5.03
	=	1.92%

Genovis AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	6.23%	/	3.80
	=	1.64%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of 1.64% mean?

Genovis AB (FRA:5GV) has a ROE % Adjusted to Book Value of 1.64% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Genovis AB and its competitors.

Is Genovis AB's ROE % Adjusted to Book Value too high?

Genovis AB's current ROE % Adjusted to Book Value is 1.64%. Overall, Genovis AB has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.

How does Genovis AB's ROE % Adjusted to Book Value compare to VRTX and REGN?

Genovis AB's ROE % Adjusted to Book Value of 1.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Genovis AB and its competitors. Genovis AB's current ROE % Adjusted to Book Value is 1.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Genovis AB stock overvalued right now?

Genovis AB (FRA:5GV) has a current ROE % Adjusted to Book Value of 1.64%. The stock's GF Value™ is €2.57, compared to a current price of €1.84 — trading 28.4% below its estimated fair value. The current ROE % Adjusted to Book Value is 1.64%. Genovis AB's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For Genovis AB (FRA:5GV), the current ROE % Adjusted to Book Value is 1.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovis AB (FRA:5GV) Overvalued in 2026?

Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued. The current stock price of €1.84 is trading 28.4% below its estimated GF Value™ of €2.57.

Key valuation signals for FRA:5GV:

ROE % Adjusted to Book Value: 1.64%
GF Value™: €2.57 vs. price of €1.84 (28.4% below fair value)
GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the FRA:5GV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovis AB Business Description

Industry Healthcare Biotechnology

Comparable Companies XSAT:HAMLET B XSAT:CURAS OSTO:BINV OSTO:MVIR OSTO:SYNACT OSTO:IBT B OSTO:FLERIE OSTO:SANION OSTO:XSPRAY OSTO:FLUO VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges GENO:Sweden

Address Kavlinge, Box 4, Lund, SWE, SE-24421

Website https://www.genovis.com

Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.

93GF Score

Get the complete analysis for FRA:5GV

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84

Price

€2.57

GF Value

View FRA:5GV Analysis

See ROE % Adjusted to Book Value data for all stocks →